Novazyme Pharmaceuticals Overview

  • Founded
  • 1999

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $215M

Novazyme Pharmaceuticals General Information


Developer of biotherapeutic products for the treatment of lysosomal storage disorders.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Primary Office
  • 353 Nassau Street
  • Princeton, NJ 08540
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novazyme Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 27-Sep-2001 $215M 0000 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 18-Apr-2001 0000 0000 Completed Generating Revenue
1. Early Stage VC (Series A) 19-Sep-2000 $8M $8M Completed Product Development
To view Novazyme Pharmaceuticals’s complete valuation and funding history, request access »

Novazyme Pharmaceuticals Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Aisling Capital Venture Capital Minority 000 0000 000000 0
Catalyst Health Ventures Venture Capital Minority 000 0000 000000 0
HealthCare Ventures Venture Capital Minority 000 0000 000000 0
Morgan Stanley Expansion Capital Growth/Expansion Majority 000 0000 000000 0
Strattech Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »